PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Endocrine
  • Metabolic

Project Aim

To develop a humanised antibody to Netrin-1 for the treatment of osteolytic bone disease

Advantage

An Anti-Netrin-1 therapeutic offers the potential to prevent the need for revision arthroplasty and prolong lifespans of prosthetic joints

Target Class

Laminin-like proteins

Modality

Antibody

Current Status

Hit to Lead. Antibody characterisation and selection prior to humanisation

Intellectual Property

Initial filings with the opportunity to create a protective IPR portfolio

Offering

Licence or shared risk collaboration

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities